MP060DETERMINING TREATMENT PREFERENCE FOR TOLVAPTAN IN AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD): DEVELOPMENT OF A DISCRETE CHOICE EXPERIMENT (DCE) FOR USE AS A CLINICAL STUDY ENDPOINT
نویسندگان
چکیده
منابع مشابه
Tolvaptan and Autosomal Dominant Polycystic Kidney Disease.
n engl j med 368;13 nejm.org march 28, 2013 1257 macrophage activation syndrome. In animals, high levels of interleukin-6 contribute to the triggering of this syndrome1; additional cytokines, including interferon-γ, interleukin-1, and interleukin-18, might be involved in maintaining and amplifying the inflammatory response.2 Indeed, interleukin-1 antagonism may be beneficial in a full-blown cas...
متن کاملCost-effectiveness of tolvaptan in autosomal dominant polycystic kidney disease.
UNLABELLED Chinese translation BACKGROUND In the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and Its Outcomes) trial, tolvaptan significantly reduced expansion of kidney volume and loss of kidney function. OBJECTIVE To determine how the benefits of tolvaptan seen in TEMPO may relate to longer-term health outcomes, such as progression to...
متن کاملHypertension in autosomal-dominant polycystic kidney disease (ADPKD)
Cardiovascular (CV) complications are the major cause of death in autosomal-dominant polycystic kidney disease (ADPKD) patients. Hypertension is common in these patients even before the onset of renal insufficiency. Blood pressure (BP) elevation is a key factor in patient outcome, mainly owing to the high prevalence of target organ damage together with a poor renal prognosis when BP is increase...
متن کاملTolvaptan in autosomal dominant polycystic kidney disease: three years' experience.
BACKGROUND AND OBJECTIVES Autosomal dominant polycystic kidney disease (ADPKD), a frequent cause of end-stage renal disease, has no cure. V2-specific vasopressin receptor antagonists delay disease progression in animal models. DESIGN, SETTING, PARTICIPANTS, AND MEASUREMENTS This is a prospectively designed analysis of annual total kidney volume (TKV) and thrice annual estimated GFR (eGFR) mea...
متن کاملTolvaptan in patients with autosomal dominant polycystic kidney disease.
BACKGROUND The course of autosomal dominant polycystic kidney disease (ADPKD) is often associated with pain, hypertension, and kidney failure. Preclinical studies indicated that vasopressin V(2)-receptor antagonists inhibit cyst growth and slow the decline of kidney function. METHODS In this phase 3, multicenter, double-blind, placebo-controlled, 3-year trial, we randomly assigned 1445 patien...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Nephrology Dialysis Transplantation
سال: 2016
ISSN: 1460-2385,0931-0509
DOI: 10.1093/ndt/gfw182.30